Your browser is no longer supported. Please, upgrade your browser.
CVM CEL-SCI Corporation monthly Stock Chart
CEL-SCI Corporation
Index- P/E- EPS (ttm)-0.82 Insider Own4.30% Shs Outstand37.45M Perf Week13.81%
Market Cap466.75M Forward P/E- EPS next Y-0.11 Insider Trans-0.30% Shs Float37.07M Perf Month4.95%
Income-29.60M PEG- EPS next Q-0.10 Inst Own31.70% Short Float24.14% Perf Quarter-4.01%
Sales0.60M P/S777.91 EPS this Y62.10% Inst Trans-6.30% Short Ratio17.67 Perf Half Y-7.51%
Book/sh0.51 P/B25.37 EPS next Y85.70% ROA-88.40% Target Price- Perf Year70.04%
Cash/sh0.56 P/C23.22 EPS next 5Y- ROE-273.10% 52W Range6.35 - 18.00 Perf YTD41.42%
Dividend- P/FCF- EPS past 5Y43.30% ROI-108.60% 52W High-28.11% Beta2.17
Dividend %- Quick Ratio4.70 Sales past 5Y11.90% Gross Margin- 52W Low103.78% ATR0.82
Employees43 Current Ratio4.90 Sales Q/Q100.00% Oper. Margin- RSI (14)55.92 Volatility6.12% 7.03%
OptionableYes Debt/Eq0.68 EPS Q/Q25.40% Profit Margin- Rel Volume0.40 Prev Close12.49
ShortableNo LT Debt/Eq0.63 Earnings- Payout- Avg Volume506.33K Price12.94
Recom2.00 SMA207.95% SMA50-0.96% SMA200-1.99% Volume203,755 Change3.60%
Jan-13-20Initiated H.C. Wainwright Buy $18
Mar-02-15Initiated Dawson James Buy $3
Oct-14-20 07:19AM  
Sep-18-20 09:00AM  
Sep-15-20 09:15AM  
Sep-11-20 09:00AM  
Sep-01-20 04:34PM  
Aug-31-20 09:00AM  
Aug-25-20 06:13AM  
Aug-11-20 08:30AM  
Aug-05-20 09:00AM  
Jul-24-20 08:30AM  
Jul-16-20 09:38AM  
Jun-30-20 08:30AM  
Jun-24-20 10:00AM  
Jun-10-20 01:30PM  
May-28-20 01:07PM  
May-11-20 08:00AM  
May-08-20 06:20AM  
May-04-20 07:15AM  
Apr-23-20 09:15AM  
Apr-08-20 08:00AM  
Mar-30-20 04:05PM  
Mar-26-20 11:05AM  
Mar-24-20 09:25AM  
Mar-23-20 09:46PM  
Mar-10-20 12:00PM  
Mar-09-20 07:55AM  
Feb-27-20 12:44PM  
Feb-26-20 03:19PM  
Feb-10-20 08:00AM  
Feb-06-20 09:00AM  
Jan-10-20 08:30AM  
Jan-07-20 02:40PM  
Dec-27-19 11:15AM  
Dec-26-19 09:59AM  
Dec-24-19 07:16AM  
Dec-23-19 04:04PM  
Dec-20-19 03:28PM  
Dec-16-19 04:15PM  
Dec-06-19 09:00AM  
Oct-29-19 07:00AM  
Oct-24-19 09:00AM  
Oct-16-19 07:30PM  
Oct-15-19 08:30AM  
Sep-25-19 11:35AM  
Sep-04-19 12:14PM  
Aug-14-19 04:20PM  
Jul-23-19 09:30AM  
Jul-08-19 09:00AM  
Jun-23-19 09:00AM  
Jun-19-19 10:30AM  
Jun-11-19 04:35PM  
Jun-10-19 09:00AM  
Jun-03-19 09:00AM  
May-29-19 01:00PM  
May-14-19 04:33PM  
May-13-19 09:00AM  
May-08-19 08:00AM  
Apr-30-19 09:00AM  
Mar-29-19 09:00AM  
Mar-26-19 06:16PM  
Mar-25-19 08:12AM  
Mar-07-19 11:00AM  
Mar-04-19 08:00AM  
Mar-01-19 11:45AM  
Feb-14-19 04:27PM  
Feb-07-19 09:00AM  
Feb-04-19 10:00AM  
Feb-01-19 11:30AM  
Jan-23-19 09:20AM  
Jan-15-19 08:00AM  
Dec-20-18 09:00AM  
Nov-23-18 08:55AM  
Oct-23-18 08:30AM  
Oct-16-18 10:55AM  
Oct-01-18 08:30AM  
Sep-28-18 08:00AM  
Sep-24-18 10:30AM  
Sep-14-18 09:00AM  
Sep-07-18 09:30AM  
Sep-05-18 09:00AM  
Aug-22-18 08:00AM  
Aug-21-18 10:00AM  
Aug-17-18 08:00AM  
Aug-15-18 08:30AM  
Aug-14-18 05:13PM  
Jul-13-18 05:10PM  
Jul-10-18 08:10AM  
Jul-09-18 09:00AM  
Jul-02-18 12:46PM  
Jun-28-18 02:56PM  
Jun-27-18 10:51AM  
Jun-11-18 09:00AM  
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAILLAVOINE BRUNO JEAN-MARIEDirectorNov 18Buy11.778009,4164,723Nov 18 10:45 AM
Watson Robert EugeneDirectorNov 18Buy11.778009,4163,181Nov 18 09:59 AM
YOUNG PETER RDirectorNov 17Buy11.688009,34325,814Nov 18 11:10 AM
CIPRIANO JOHNSenior Vice PresidentNov 13Sale12.7310,000127,29073,108Nov 16 04:49 PM
YOUNG PETER RDirectorNov 04Buy11.342,00022,67025,014Nov 06 04:26 PM
YOUNG PETER RDirectorNov 04Buy11.391,00011,39023,014Nov 06 04:26 PM
YOUNG PETER RDirectorFeb 26Buy10.839239,99622,014Feb 27 07:49 AM
ZIMMERMAN DANIEL HSenior Vice PresidentFeb 26Buy10.839239,996114,387Feb 27 07:45 AM
PRICHEP PATRICIA BSenior Vice PresidentFeb 26Buy10.831,84720,003205,275Feb 27 07:37 AM
KERSTEN GEERT RChief Executive OfficerFeb 26Buy10.834,61750,0021,119,155Feb 27 07:33 AM
Watson Robert EugeneDirectorFeb 26Buy10.839239,9962,381Feb 27 07:57 AM
BAILLAVOINE BRUNO JEAN-MARIEDirectorFeb 26Buy10.839239,9963,923Feb 27 07:53 AM
KERSTEN GEERT RChief Executive OfficerJan 10Buy7.546,63149,9981,114,538Jan 13 08:10 AM